Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer

Last updated: December 26, 2023
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

2

Condition

Colorectal Cancer

Colon Cancer

Colon Cancer; Rectal Cancer

Treatment

mFOLFOXIRI

mFOLFOX6

mFOLFOXIRI + Cadonilimab

Clinical Study ID

NCT05571644
GIHSYSU-15
  • Ages 18-70
  • All Genders

Study Summary

Neoadjuvant chemoradiotherapy (CRT) followed by total mesenteric excision (TME) and adjuvant chemotherapy was the standard of treatment for locally advanced rectal cancer (LARC) in the past two decades. The main obstacles for improving survival benefit of LARC was distant metastasis. Recently, total neoadjuvant therapy (TNT) had been recommended as new preferred option for LARC. Induction chemotherapy with FOLFOXIRI followed by CRT or short-course radiotherapy followed by FOLFOX chemotherapy had improved survival benefit for LARC.

Neoadjuvant immunotherapy had also been explored in pMMR patients with CRC. In the NICHE trial, neoadjuvant therapy with 2 dose of nivolumab and 1 dose of ipilimumab led to 29% of pathological response and 13% of pCR. Cadonilimab (AK104) was a PD-1/CTLA-4 bi-specific antibody. Here, we tried to explore the efficacy of Neoadjuvant Treatment With mFOLFOXIRI with or without Cadonilimab (AK104) Versus mFOLFOX6 in LARC.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged 18-70;
  2. Colorectal adenocarcinoma with definite histological evidence;
  3. ECOG Performance status score is 0-1
  4. Colon cancer was evaluated as T3>5mm or T4 by contrast-enhanced CT examination of thechest, abdomen and pelvis, and distant displacement was excluded; Rectal cancer wasgraded as T3-4 and/or N+ by pelvic contrast-enhanced MRI examination, and the lowermargin of the tumor was less than 12cm away from the anal margin. Distant metastasiswas excluded by chest, abdomen and pelvis CT.
  5. The primary rectal tumor was assessed as complete resections by a multidisciplinarycollaboration group on colorectal cancer, including at least 2 gastrointestinalsurgeons and 1 radiologist;
  6. No previous systemic antitumor therapy for colorectal cancer, including cytotoxicdrugs, immunotherapy, molecular targeted therapy, etc.;
  7. Adequate organ function based on the following laboratory test values obtained within 7 days prior to treatment: Hemoglobin ≥90g/L, neutrophil count ≥1.5×109/L, platelet count ≥75×109/L, serum totalbilirubin ≤1.5× upper limit of normal value (UNL), aspartate transferase ≤2×UNL,alanine transferase ≤3×UNL, serum creatinine ≤1.5×UNL;
  8. Willing and able to comply with research protocols and visit plans.

Exclusion

Exclusion Criteria:

  1. The patient was complicated with obstruction, active bleeding, or perforation andrequired emergency surgery or stent placement;
  2. Active, known or suspected autoimmune diseases (except type I diabetes, residualhypothyroidism requiring only hormone replacement due to autoimmune conditions, orautoimmune diseases that are not expected to recur in the absence of externaltriggers);
  3. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiencysyndrome (AIDS), untreated active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500IU/ml; Hepatitis C, defined as HCV-RNA above the detection limit of the assay) orco-infection with hepatitis B and C;
  4. Known allergy to the treatment drug or allergy or intolerance to its ingredients;
  5. Major surgery or severe trauma, such as laparotomy, thoracotomy, laparoscopic organresection, etc. within the previous 4 weeks (the surgical incision should becompletely healed before enrollment);
  6. Existing or coexisting other active malignancies (except those that have been treatedwith curative therapy and remain disease-free for more than 5 years or carcinoma insitu that can be cured by adequate treatment);
  7. Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody andanti-cytotoxic T-lymphocyte-associated protein 4 (Cytotoxic T-lymphocyte-associatedprotein 4) antibody. Ctla-4) antibodies or other drugs/antibodies that act on T-cellcostimulatory or checkpoint pathways;
  8. Had active coronary artery disease, severe/unstable angina pectoris or newly diagnosedangina pectoris or myocardial infarction within 6 months prior to study enrollment;Thrombotic or embolic events, such as cerebrovascular accident (including transientischemic attack), pulmonary embolism, deep vein thrombosis, occurred within theprevious 6 months;
  9. The New York Heart Association (NYHA) class II or higher congestive Heart failure (seeAppendix 3);
  10. Presence of active inflammatory bowel disease or other colorectal disease leading tochronic diarrhea;
  11. The presence of any toxicity (Common Terminology Criteria for Adverse Events, CTCAE) (version 5.0) grade 1 or above (except anemia, alopecia, and skin pigmentation) causedby previous treatment that has not subsided;
  12. Previous or current history of pulmonary fibrosis, interstitial pneumonia,pneumoconiosis, drug-related pneumonia, severe impairment of pulmonary function andother lung diseases;
  13. Active tuberculosis (TB), receiving anti-TB therapy or receiving anti-TB therapywithin 1 year before the first dose;
  14. Persons with known syphilis infection requiring treatment;
  15. Had used immunosuppressive drugs within 4 weeks before the first dose, Does notinclude the nasal spray, inhalation, or other ways of topical corticosteroids orphysiological doses of systemic corticosteroids (i.e., no more than 10 mg/dayprednisone or other equivalent dose glucocorticoids), allows for prevention ofallergic reactions, or treatment of diseases such as asthma, chronic obstructivepulmonary disease of breathing difficulties for the temporary use of glucocorticoid;
  16. Receive live attenuated vaccine within 4 weeks before the first dose or during thestudy period;
  17. Pregnant or lactating women; Women of reproductive age (< 2 years after lastmenstruation) who do not use or refuse to use effective non-hormonal contraception ormen at risk of having children.

Study Design

Total Participants: 143
Treatment Group(s): 3
Primary Treatment: mFOLFOXIRI
Phase: 2
Study Start date:
July 10, 2023
Estimated Completion Date:
December 15, 2025

Study Description

This study was a prospective, randomized, uncontrolled phase II trial to evaluate the efficacy of mFOLFOXIRI combined with AK104 neoadjuvant therapy versus mFOLFOX6 neoadjuvant therapy in LARC.

The inclusion criteria: locally advanced colon cancer (T3>5mm or T4 on enhanced CT assessment, with distant metastasis excluded); Locally advanced rectal cancer (pelvic MR assessment as stage ii-iii, less than 12cm from the anal margin, no distant metastasis), primary tumor location and TNM stage were stratified factors.

Group A: mFOLFOXIRI combined with Cadonilimab (AK104) for 6 cycles before surgery

Group B: 6 cycles of neoadjuvant chemotherapy with mFOLFOX6 before surgery

Group C: 6 cycles of neoadjuvant chemotherapy with mFOLFOXIRI before surgery

All groups were re-evaluated after 3 cycles and 6 cycles of treatment. If surgery was feasible after multidisciplinary evaluation, TME resection was performed, and adjuvant treatment was performed according to standard treatment after operation. For locally advanced rectal cancer, preoperative pelvic enhanced MRI was used to evaluate tumor regression after 6 cycles of preoperative treatment. For patients who still had MRF+ and/or T4 after treatment, additional short-course radiotherapy was allowed.

Connect with a study center

  • Gastrointestinal Hospital, Sun Yat-sen University

    Guangzhou, Guangdong 510655
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.